The stock decreased 0.64% or $0.01 during the last trading session, reaching $1.55. Four analysts have made estimates for Novavax's earnings, with estimates ranging from ($0.15) to ($0.13). Brown Advisory Inc. now owns 162,700 shares of the biopharmaceutical company's stock worth $185,000 after purchasing an additional 69,600 shares in the last quarter.
For the ongoing Fiscal Quarter, 7 analysts have an average earnings forecast of $-0.14 per share. According to the Analysts, the Low Earnings estimate for the current quarter is $-0.17, while the High earnings estimate is $-0.12.Comparatively, EPS for the same quarter past year was $-0.15. MetLife Investment Advisors LLC purchased a new position in shares of Novavax during the fourth quarter worth about $172,000.
Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Wednesday, March 14th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.01).
For the current quarter Novavax Inc (NASDAQ:NVAX) has average revenue estimates of $10.43 Million, a total number of 7 analysts provided estimations over revenues. Novavax's revenue for the quarter was up 92.6% compared to the same quarter past year. They are also projecting the Low EPS estimate of $-0.17 and the High EPS estimate of $-0.12.
Several equities analysts recently issued reports on NVAX shares. Finally, BidaskClub raised Novavax from a "hold" rating to a "buy" rating in a research report on Thursday, March 15th. Chardan Capital reiterated a "hold" rating on shares of Novavax in a report on Thursday, March 1st. S&P Equity Research dropped their price objective on shares of Novavax from $1.81 to $1.35 in a research note on Wednesday, January 10th. At the time of writing, this stock has a consensus price target set at $4.00 and average analyst rating set to Hold.
SUPERVALU Inc. (SVU) analysts on average have given a price target of $4 on SVU stock. Schwab Charles Investment Management Inc. now owns 1,443,013 shares of the biopharmaceutical company's stock valued at $1,790,000 after buying an additional 217,995 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its position in shares of Novavax by 349.8% during the fourth quarter. The fund owned 492,492 shares of the biopharmaceutical company's stock after acquiring an additional 37,793 shares during the quarter. The short sellers then promise to replace the stock in the future and makes dividend payments out of their own pockets to cover the dividend income that is no longer exists on the original, now borrowed and sold, shares. Aperio Group LLC lifted its holdings in Novavax by 121.1% during the fourth quarter. Fisher Asset Management LLC acquired a new position in Novavax in the fourth quarter valued at about $179,000. Bank of New York Mellon Corp boosted its position in Novavax by 2.5% during the 4th quarter. This is what we find in Novavax Inc (NASDAQ:NVAX). The overall volume in the last trading session was 3.59 million shares. The company has a market cap of $595.29, a price-to-earnings ratio of -2.46 and a beta of 2.43. The company has a debt-to-equity ratio of -3.12, a quick ratio of 2.76 and a current ratio of 2.76. The stock appeared $2.75 above its 52-week highs and is down -6.02% for the last five trades.
Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants.
Proposed new European Union budget to be unveiled
Most of that money now goes to eastern former Soviet bloc countries which are still catching up economically. Reductions will hit the so-called cohesion funds used for development in poorer European nations.